Kimberly-Clark
KMB
$100.50
-2.01%
Kimberly-Clark Corp. is a leading global manufacturer in the household and personal products industry, with a core business centered on essential consumer goods such as diapers (Huggies), feminine care (Kotex), adult care (Depend), and tissue products (Kleenex, Cottonelle). The company operates as a dominant market player with a portfolio of trusted, everyday brands, and also serves the professional segment with workplace safety and sanitation solutions. The current investor narrative is heavily focused on the company's planned acquisition of Kenvue's consumer health portfolio in the second half of 2026, a major strategic move aimed at expanding its product mix, alongside ongoing debates about its ability to navigate input cost pressures and deliver stable growth in a competitive, defensive sector.…
KMB
Kimberly-Clark
$100.50
Related headlines
Investment Opinion: Should I buy KMB Today?
Rating: Hold. The core thesis is that KMB presents a classic 'value trap' scenario—its cheap valuation and high yield are attractive, but they are justified by fundamental deterioration and high financial risk, making a near-term catalyst for outperformance unlikely.
The Hold rating is supported by four specific data points: 1) The forward P/E of 13.55x is below sector averages for stable consumer staples, suggesting limited multiple compression risk from current levels. 2) The 4.94% dividend yield is well-covered by an 82% payout ratio and robust $2.38B FCF. 3) The stock trades at only 74.6% of its 52-week range, indicating much bad news is priced in. 4) Analyst sentiment is mixed but not universally negative, with an average EPS estimate implying potential stability.
The two biggest risks invalidating a neutral stance are: 1) Revenue decline accelerating beyond -17% YoY, signaling a loss of pricing power and market share. 2) A deterioration in credit metrics leading to a rating downgrade, which would increase financing costs for the Kenvue deal. This Hold would upgrade to a Buy if quarterly revenue growth turns positive, or downgrade to a Sell if the debt-to-equity ratio climbs above 5.5. The stock is fairly valued relative to its challenged growth profile but undervalued if management can successfully execute a turnaround.
Sign up to view all
KMB 12-Month Price Forecast
The AI assessment is neutral with medium confidence. KMB is a bifurcated story: its valuation and yield are compelling for income-focused, risk-averse investors, but its deteriorating fundamentals and balance sheet risk make it unsuitable for growth-oriented portfolios. The stock is likely to remain range-bound as investors await clarity on the Kenvue acquisition and evidence of top-line stabilization. The stance would upgrade to bullish if the next two quarterly reports show a clear inflection in revenue growth trends. It would turn bearish if the stock breaks below its 52-week low of $92.42 on high volume, signaling a breakdown of technical support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $130.65 and implied upside of +30.0% versus the current price.
Average Target
$130.65
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$80 - $131
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, signaling this large-cap stock has lower institutional research focus than peers. The consensus sentiment appears mixed to neutral, as evidenced by recent institutional ratings which include actions like 'Hold' from Deutsche Bank and UBS, an 'Overweight' from Piper Sandler, and a 'Sell' from Citigroup, reflecting uncertainty around the Kenvue acquisition and growth trajectory. The target price range implied by EPS estimates is wide, with a low EPS estimate of $8.99 and a high of $10.03, translating to a significant spread in potential valuation outcomes; the high target likely assumes successful integration of the Kenvue assets and margin recovery, while the low target prices in execution risks and continued top-line pressure. The limited coverage and wide estimate dispersion typically lead to higher volatility and less efficient price discovery for the stock.
Bulls vs Bears: KMB Investment Factors
The evidence currently tilts bearish, as the company's severe revenue contraction, high leverage, and persistent technical downtrend outweigh its defensive attributes and valuation appeal. The most important tension in the investment debate is the conflict between KMB's undemanding valuation/strong cash flow and its deteriorating fundamental growth profile. The resolution hinges on whether the Kenvue acquisition and internal execution can reignite top-line growth before leverage and sentiment pressures cause further multiple compression. If growth stabilizes, the valuation provides a margin of safety; if not, the stock risks becoming a value trap.
Bullish
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $2.38 billion. This provides significant financial flexibility to fund the dividend, service its high debt, and potentially support the upcoming Kenvue acquisition.
- Undemanding Valuation Multiples: KMB trades at a trailing P/E of 16.63x and a forward P/E of 13.55x, which is near the lower end of its historical range. Its EV/EBITDA of 12.94x and P/S of 1.95x suggest the stock is not expensive relative to its cash flows and sales, pricing in current challenges.
- Defensive Profile with Low Beta: The stock has a beta of 0.302, indicating it is roughly 70% less volatile than the broader market. This low correlation provides a defensive characteristic, making it a potential portfolio stabilizer during market downturns.
- Attractive Dividend Yield: KMB offers a dividend yield of approximately 4.94% with a payout ratio of 82%. This high, well-covered yield provides a tangible return while investors wait for a potential turnaround, supported by the strong FCF.
Bearish
- Persistent Revenue Contraction: The company is experiencing significant top-line pressure, with Q4 2025 revenue of $4.08B representing a -17.21% YoY decline and a sequential drop from Q3. This indicates fundamental weakness in the core business, not just cyclical factors.
- Extremely High Financial Leverage: KMB's balance sheet is heavily leveraged, with a debt-to-equity ratio of 4.86. While FCF is strong, this high debt load increases financial risk, limits strategic optionality, and could pressure the company if interest rates remain elevated.
- Severe Technical Downtrend: The stock is down -19.85% over the past year, drastically underperforming the S&P 500's +24.99% gain. Trading near 74.6% of its 52-week range, it remains in a bearish channel, indicating sustained negative momentum and investor sentiment.
- Weak Short-Term Liquidity: The current ratio of 0.75 indicates the company may have difficulty covering its short-term obligations with its short-term assets. This modest liquidity position adds operational risk on top of the high long-term debt.
KMB Technical Analysis
The stock is in a sustained downtrend over the past year, evidenced by a 1-year price change of -19.85%, significantly underperforming the S&P 500's 24.99% gain. With a current price near $102.56, it is trading at approximately 74.6% of its 52-week range (based on a 52-week high of $137.46 and low of $92.42), positioning it closer to the lower bound and suggesting a potential value opportunity, though it remains in a bearish channel. Recent momentum shows a modest short-term recovery, with a 1-month price change of +6.31% and a 3-month change of +4.44%, indicating a potential stabilization or reversal attempt after the severe yearly decline; however, this nascent uptick is occurring against a backdrop of extreme relative weakness, with a 1-year relative strength of -44.84 versus the market. Key technical support is firmly established at the 52-week low of $92.42, while resistance sits at the yearly high of $137.46; a sustained breakout above the recent trading range near $110 would be needed to signal a more convincing trend reversal. The stock exhibits low market-correlated volatility with a beta of 0.302, meaning it is roughly 70% less volatile than the SPY, which is typical for a defensive consumer staples name and implies lower systematic risk but also less explosive upside potential.
Beta
0.30
0.30x market volatility
Max Drawdown
-35.3%
Largest decline past year
52-Week Range
$92-$137
Price range past year
Annual Return
-21.7%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | +1.4% | -0.2% |
| 3m | +1.6% | +14.0% |
| 6m | -0.6% | +7.8% |
| 1y | -21.7% | +25.3% |
| ytd | -0.9% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Revenue growth has been stagnant to slightly negative, with the most recent quarterly revenue of $4.08 billion representing a year-over-year decline of -17.21%, and a sequential decline from the prior quarter's $4.13 billion, indicating persistent top-line pressure. The company remains profitable, posting net income of $499 million for Q4 2025, translating to a net margin of 12.23%, while its gross margin for the quarter was 35.91%, showing resilience in profitability despite revenue headwinds. Profitability metrics are mixed, with a trailing twelve-month free cash flow of $2.38 billion providing strong cash generation, but the balance sheet carries significant leverage, evidenced by a debt-to-equity ratio of 4.86 and a current ratio of 0.75, indicating a high degree of financial leverage and modest short-term liquidity, though the robust free cash flow helps service this debt. The return on equity is an exceptionally high 134.55%, but this is largely a function of the high financial leverage rather than exceptional operational returns, as the return on assets is a more modest 10.16%.
Quarterly Revenue
$4.1B
2025-12
Revenue YoY Growth
-0.17%
YoY Comparison
Gross Margin
+0.35%
Latest Quarter
Free Cash Flow
$2.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is 16.63x, while the forward PE is 13.55x, with the forward multiple's discount implying the market expects modest earnings growth or a normalization from potentially elevated trailing profits. Compared to sector averages, the stock's trailing PE of 16.63x is below the typical range for stable consumer defensive names, and its Price-to-Sales ratio of 1.95x and EV/EBITDA of 12.94x suggest a valuation that is not demanding relative to its cash flow and sales. Historically, the current trailing PE of 16.63x sits near the lower end of its own historical range observed over recent quarters, which has seen figures as high as 114.37x (in Q2 2023 during an earnings anomaly) and as low as 13.17x, indicating the stock is trading at a relatively undemanding multiple compared to its own history, potentially pricing in the current growth challenges.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~114x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, centered on an unsustainable revenue trajectory and a highly leveraged balance sheet. The -17.21% YoY revenue decline in Q4 2025 signals core business erosion, not a temporary setback. The debt-to-equity ratio of 4.86 is exceptionally high, and while the $2.38B TTM FCF provides a cushion, it commits a large portion of cash flow to debt service, limiting reinvestment. The current ratio of 0.75 indicates potential strain in meeting short-term liabilities, adding operational friction.
Market & Competitive Risks include valuation compression and acquisition execution risk. The stock's -44.84 relative strength vs. the market over one year shows it is deeply out of favor. While valuation multiples like the 13.55x forward P/E appear cheap, they could compress further if revenue declines persist. The planned Kenvue acquisition, while a potential catalyst, carries significant integration risk, financing complexity, and could distract management during a period of core business weakness, as highlighted in recent M&A commentary.
Worst-Case Scenario involves a continuation of revenue declines coupled with a failed acquisition strategy, leading to a credit rating downgrade and a dividend cut. In this adverse scenario, the stock could re-test its 52-week low of $92.42, representing a downside of approximately -10% from the current price near $102.56. A more severe bear case, factoring in the stock's -35.31% max drawdown potential, could see a decline towards the $85-$90 range if earnings estimates are cut significantly and the high-yield investor base exits, resulting in a potential loss of -15% to -20%.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Extremely high leverage with a debt-to-equity ratio of 4.86, which could strain cash flow and limit flexibility. 2) Operational Risk: Persistent revenue contraction, with the latest quarter down -17.21% YoY, indicating core business weakness. 3) Execution Risk: The large and complex acquisition of Kenvue's portfolio, slated for H2 2026, carries significant integration and financing challenges. 4) Sentiment Risk: The stock is in a severe technical downtrend, down -19.85% over the past year, and could face further selling pressure if the dividend yield becomes less attractive relative to rising rates.
The 12-month forecast for KMB is one of range-bound trading with a neutral bias, based on a weighted probability of three scenarios. The Base Case (60% probability) sees the stock trading between $100 and $115, as revenue stabilizes but growth remains elusive. The Bull Case (25% probability) projects a move to $125-$137 on successful acquisition progress and growth inflection. The Bear Case (15% probability) warns of a drop to $92-$98 if operational deterioration continues. The most likely outcome is the Base Case, assuming the company's strong free cash flow and dividend provide a floor, while fundamental headwinds cap the upside.
KMB appears fairly valued to slightly undervalued based on traditional metrics, but this is relative to its challenged fundamentals. Its forward P/E of 13.55x and EV/EBITDA of 12.94x are not demanding for a consumer staples leader and sit near the lower end of its historical range. Compared to the sector, these multiples suggest the market is not paying a premium. However, the valuation accurately reflects the company's negative revenue growth and high debt load. It is undervalued only if one believes management can stabilize the top line and successfully integrate the Kenvue acquisition, leading to a re-rating.
KMB is a conditional buy, primarily for a specific investor profile. For an investor seeking high current income and who has a long-term, patient outlook, KMB's 4.94% yield and undemanding forward P/E of 13.55x can be attractive. However, it is not a good buy for growth investors, as the company faces severe revenue headwinds (-17.21% YoY) and carries high financial leverage (D/E of 4.86). The investment thesis relies heavily on the successful execution and integration of the Kenvue acquisition in late 2026. Therefore, it is a good buy only for income-focused investors willing to accept the risks of a turnaround story.
KMB is unequivocally suitable only for long-term investment, with a minimum suggested holding period of 3-5 years. Its low beta of 0.302 means it lacks the volatility typically sought by short-term traders. The investment thesis is a long-duration turnaround story centered on the Kenvue acquisition in late 2026 and a potential stabilization of the core business. The high dividend yield is a component of total return that accrues over time. Short-term investors would be better served elsewhere, as the stock lacks near-term catalysts and is mired in a technical downtrend. Patient, income-focused investors are the appropriate audience.